vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and OppFi Inc. (OPFI). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $85.6M, roughly 2.0× OppFi Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 5.9%). Over the past eight quarters, OppFi Inc.'s revenue compounded faster (16.3% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
OppFi Inc. is a US-headquartered financial technology firm that provides responsible, accessible financial solutions including installment loans, credit-building tools and related support services to consumers underserved by traditional banking institutions, prioritizing fair terms to help users boost their long-term financial wellness.
ESPR vs OPFI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $85.6M |
| Net Profit | — | $16.8M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 36.1% |
| Net Margin | — | 19.7% |
| Revenue YoY | 143.7% | 5.9% |
| Net Profit YoY | — | 400.3% |
| EPS (diluted) | $0.32 | $1.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $85.6M | ||
| Q3 25 | $87.3M | $104.6M | ||
| Q2 25 | $82.4M | $100.2M | ||
| Q1 25 | $65.0M | $90.8M | ||
| Q4 24 | $69.1M | $80.8M | ||
| Q3 24 | $51.6M | $91.2M | ||
| Q2 24 | $73.8M | $86.3M | ||
| Q1 24 | $137.7M | $63.2M |
| Q4 25 | — | $16.8M | ||
| Q3 25 | $-31.3M | $41.6M | ||
| Q2 25 | $-12.7M | $-20.8M | ||
| Q1 25 | $-40.5M | $-11.4M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-29.5M | $4.3M | ||
| Q2 24 | $-61.9M | $3.1M | ||
| Q1 24 | $61.0M | $5.5M |
| Q4 25 | 50.6% | 36.1% | ||
| Q3 25 | -11.4% | 46.3% | ||
| Q2 25 | 8.6% | 44.7% | ||
| Q1 25 | -34.0% | 46.8% | ||
| Q4 24 | -6.4% | 30.5% | ||
| Q3 24 | -31.0% | 38.5% | ||
| Q2 24 | 3.5% | 34.2% | ||
| Q1 24 | 52.5% | 8.4% |
| Q4 25 | — | 19.7% | ||
| Q3 25 | -35.9% | 39.8% | ||
| Q2 25 | -15.4% | -20.7% | ||
| Q1 25 | -62.2% | -12.5% | ||
| Q4 24 | — | -6.9% | ||
| Q3 24 | -57.2% | 4.7% | ||
| Q2 24 | -83.9% | 3.6% | ||
| Q1 24 | 44.3% | 8.8% |
| Q4 25 | $0.32 | $1.48 | ||
| Q3 25 | $-0.16 | $0.77 | ||
| Q2 25 | $-0.06 | $-0.78 | ||
| Q1 25 | $-0.21 | $-0.48 | ||
| Q4 24 | $-0.14 | $-0.11 | ||
| Q3 24 | $-0.15 | $0.21 | ||
| Q2 24 | $-0.33 | $0.16 | ||
| Q1 24 | $0.34 | $0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $49.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $58.5M |
| Total Assets | $465.9M | $754.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $49.5M | ||
| Q3 25 | $92.4M | $45.5M | ||
| Q2 25 | $86.1M | $45.2M | ||
| Q1 25 | $114.6M | $58.0M | ||
| Q4 24 | $144.8M | $61.3M | ||
| Q3 24 | $144.7M | $44.8M | ||
| Q2 24 | $189.3M | $46.6M | ||
| Q1 24 | $226.6M | $47.2M |
| Q4 25 | $-302.0M | $58.5M | ||
| Q3 25 | $-451.4M | $49.4M | ||
| Q2 25 | $-433.5M | $13.4M | ||
| Q1 25 | $-426.2M | $22.6M | ||
| Q4 24 | $-388.7M | $32.8M | ||
| Q3 24 | $-370.2M | $34.9M | ||
| Q2 24 | $-344.2M | $18.6M | ||
| Q1 24 | $-294.3M | $18.2M |
| Q4 25 | $465.9M | $754.1M | ||
| Q3 25 | $364.0M | $720.6M | ||
| Q2 25 | $347.1M | $673.4M | ||
| Q1 25 | $324.0M | $640.1M | ||
| Q4 24 | $343.8M | $641.2M | ||
| Q3 24 | $314.1M | $619.3M | ||
| Q2 24 | $352.3M | $573.1M | ||
| Q1 24 | $373.1M | $563.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $401.3M |
| Free Cash FlowOCF − Capex | — | $382.2M |
| FCF MarginFCF / Revenue | — | 446.6% |
| Capex IntensityCapex / Revenue | 0.0% | 22.3% |
| Cash ConversionOCF / Net Profit | — | 23.82× |
| TTM Free Cash FlowTrailing 4 quarters | — | $652.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $401.3M | ||
| Q3 25 | $-4.3M | $105.1M | ||
| Q2 25 | $-31.4M | $95.6M | ||
| Q1 25 | $-22.6M | $83.7M | ||
| Q4 24 | $-35.0M | $323.8M | ||
| Q3 24 | $-35.3M | $77.6M | ||
| Q2 24 | $-7.2M | $77.3M | ||
| Q1 24 | $53.8M | $74.4M |
| Q4 25 | — | $382.2M | ||
| Q3 25 | — | $99.9M | ||
| Q2 25 | — | $91.0M | ||
| Q1 25 | — | $79.3M | ||
| Q4 24 | — | $310.8M | ||
| Q3 24 | $-35.5M | $73.7M | ||
| Q2 24 | $-7.3M | $74.7M | ||
| Q1 24 | $53.8M | $72.3M |
| Q4 25 | — | 446.6% | ||
| Q3 25 | — | 95.6% | ||
| Q2 25 | — | 90.8% | ||
| Q1 25 | — | 87.4% | ||
| Q4 24 | — | 384.6% | ||
| Q3 24 | -68.7% | 80.8% | ||
| Q2 24 | -9.9% | 86.6% | ||
| Q1 24 | 39.0% | 114.4% |
| Q4 25 | 0.0% | 22.3% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.0% | 4.6% | ||
| Q1 25 | 0.0% | 4.8% | ||
| Q4 24 | 0.0% | 16.1% | ||
| Q3 24 | 0.3% | 4.3% | ||
| Q2 24 | 0.1% | 3.0% | ||
| Q1 24 | 0.1% | 3.4% |
| Q4 25 | — | 23.82× | ||
| Q3 25 | — | 2.52× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 18.19× | ||
| Q2 24 | — | 25.21× | ||
| Q1 24 | 0.88× | 13.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
OPFI
Segment breakdown not available.
